Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May;39(5):905-913.
doi: 10.1111/liv.14074. Epub 2019 Mar 19.

The effect of oral contraceptive pill cessation on hepatocellular adenoma diameter: A retrospective cohort study

Martijn P D Haring  1 , Annette S H Gouw  2 , Robbert J de Haas  3 , Frans J C Cuperus  4 , Koert P de Jong  1 , Vincent E de Meijer  1
Affiliations

The effect of oral contraceptive pill cessation on hepatocellular adenoma diameter: A retrospective cohort study

Martijn P D Haring et al. Liver Int. 2019 May.

Abstract

Background & aims: Hepatocellular adenomas (HCA) are rare, hormone-driven, benign liver tumours. HCA >50 mm are associated with haemorrhage and malignant transformation. Guidelines recommend cessation of oral contraceptive pills (OCP) for size reduction; however, it is currently unknown how HCA respond to cessation of OCP. We sought to investigate the effect of OCP cessation on HCA size.

Methods: A retrospective cohort study was performed including HCA patients who stopped OCP intake within 6 months of imaging between 2005 and 2018. Biometrics and hormonal medication use were evaluated with self-designed questionnaires. Response of the largest HCA was evaluated according to Response Evaluation Criteria in Solid Tumours (RECISTv1.1). Cox regression was performed for analysis of factors influencing HCA regression.

Results: Seventy-eight HCA patients were included, diagnosed at a median (interquartile range) age of 32 (26-41) years. Follow-up was 1.6 (0.4-2.9) years. HCA size at diagnosis ranged 10-167 mm. After a median time of 1.3 (0.6-2.6) years after OCP cessation, 37.2% of HCA showed ≥30% regression, 5.1% complete regression, 56.4% stability and 1.3% progression. No HCA-induced complications were observed during follow-up. Cox regression analysis demonstrated a significant association of HCA size with rate of regression; 50 ≤ HCA < 100 mm (HR 2.4, 95% CI 1.1-5.3; P < 0.05), HCA ≥ 100 mm (HR 8.3, 95% CI 3.3-21.6; P < 0.001).

Conclusions: Ninety-eight per cent of HCA remained stable or regressed after OCP cessation. A longer wait-and-see period was associated with a larger proportion of regressing HCA, without HCA-related complications during follow-up.

Keywords: hepatocellular adenoma; oral contraceptive pill; regression; treatment algorithm.

PubMed Disclaimer

Conflict of interest statement

The authors do not have any disclosures to report.

Figures

Figure 1
Figure 1
Flowchart of included patients. Abbreviations: HCA, hepatocellular adenoma; GSD, glycogen storage disease; HNF1A‐MODY, hepatocyte nuclear factor 1a inactivated maturity onset diabetes of the young; OCP, oral contraceptive pill.
Figure 2
Figure 2
Spider plot of the relative change of largest HCA diameter from baseline over time for all evaluable patients (n = 78), defined as those with baseline tumour assessments and at least one postbaseline assessment. Lines are colour coded based on overall response. Horizontal dashed lines represent Response Evaluation Criteria In Solid Tumours version 1.1 guideline for partial response (≥30% decrease in target lesion) and progressive disease (≥20% increase in target lesion). Abbreviations: HCA, hepatocellular adenoma; OCP, oral contraceptive pill. Legend: Blue, HCA diameter <50 mm; Orange, HCA diameter >50 mm; Green, HCA diameter >50 mm at baseline, regression to <50 mm size; Red triangle, surgical intervention; Red circle, percutaneous intervention
Figure 3
Figure 3
(A‐D) Kaplan‐Meier curves for the percentage of HCA showing 30% or more regression. (A) All HCA, (B) subdivided by initial HCA diameter, (C) duration of OCP use (*22 missing cases) and (D) BMI (*7 missing cases). HCA, hepatocellular adenoma; OCP, oral contraceptive pill; BMI, body mass index
See this image and copyright information in PMC

References

    1. Rooks JB, Ory HW, Ishak KG, et al. Epidemiology of hepatocellular adenoma. JAMA. 1979;242:644. - PubMed
    1. Edmondson HA, Henderson B, Benton B. Liver‐cell adenomas associated with use of oral contraceptives. N Engl J Med. 1976;294:470‐472. - PubMed
    1. Nault JC, Bioulac‐Sage P, Zucman‐Rossi J. Hepatocellular benign tumors‐from molecular classification to personalized clinical care. Gastroenterology. 2013;144:888‐902. - PubMed
    1. Dokmak S, Paradis V, Vilgrain V, et al. A single‐center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology. 2009;137:1698‐1705. - PubMed
    1. Van Aalten SM, De Man RA, Ijzermans J, Terkivatan T. Systematic review of haemorrhage and rupture of hepatocellular adenomas. Br J Surg. 2012;99:911‐916. - PubMed